End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
189,500 KRW | -0.84% | +5.87% | -5.96% |
Jun. 07 | Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan | MT |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Sales 2024 * | 3,485B 2.53B | Sales 2025 * | 4,155B 3.02B | Capitalization | 38,998B 28.31B |
---|---|---|---|---|---|
Net income 2024 * | 540B 392M | Net income 2025 * | 1,100B 799M | EV / Sales 2024 * | 11.4 x |
Net Debt 2024 * | 721B 523M | Net cash position 2025 * | 106B 76.6M | EV / Sales 2025 * | 9.36 x |
P/E ratio 2024 * |
74.8
x | P/E ratio 2025 * |
36.4
x | Employees | 2,034 |
Yield 2024 * |
0.23% | Yield 2025 * |
0.25% | Free-Float | 66.01% |
1 day | -0.84% | ||
1 week | +5.87% | ||
Current month | +7.55% | ||
1 month | -1.76% | ||
3 months | +5.10% | ||
6 months | +13.00% | ||
Current year | -5.96% |
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.14% | 2 M€ | -14.14% | ||
0.99% | 11 M€ | -.--% | - | |
0.53% | 15 M€ | +15.72% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 189,500 | -0.84% | 541,848 |
24-06-07 | 191,100 | +0.42% | 494,141 |
24-06-05 | 190,300 | +1.17% | 890,135 |
24-06-04 | 188,100 | +5.08% | 1,291,227 |
End-of-day quote Korea S.E., June 09, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.96% | 28.37B | |
+49.41% | 56.95B | |
+41.65% | 40.26B | |
-6.72% | 39.32B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B | |
-9.26% | 11.05B |
- Stock Market
- Equities
- A068270 Stock